KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Net Income: 2010-2024

Historic Net Income for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to $73.9 million.

  • Supernus Pharmaceuticals' Net Income fell 217.20% to -$45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.1 million, marking a year-over-year decrease of 131.95%. This contributed to the annual value of $73.9 million for FY2024, which is 5512.84% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Net Income stood at $73.9 million for FY2024, which was up 5,512.84% from $1.3 million recorded in FY2023.
  • Supernus Pharmaceuticals' Net Income's 5-year high stood at $127.0 million during FY2020, with a 5-year trough of $1.3 million in FY2023.
  • Moreover, its 3-year median value for Net Income was $60.7 million (2022), whereas its average is $45.3 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Net Income plummeted by 97.83% in 2023 and then surged by 5,512.84% in 2024.
  • Supernus Pharmaceuticals' Net Income (MRY) stood at $127.0 million in 2020, then tumbled by 57.92% to $53.4 million in 2021, then increased by 13.64% to $60.7 million in 2022, then plummeted by 97.83% to $1.3 million in 2023, then soared by 5,512.84% to $73.9 million in 2024.
  • Its last three reported values are $73.9 million in FY2024, $1.3 million for FY2023, and $60.7 million during FY2022.